Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome

Fertility and Sterility

Volumn 87, Issue 4, 2007, Pages 862-869

  Antoine, Heath J ^a   Pall, Marita ^a   Trader, Belynda C ^a   Chen, Yii Der I ^a,b   Azziz, Ricardo ^a,b   Goodarzi, Mark O ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

insulin resistance; Peroxisome proliferator activated receptor gamma; polycystic ovary syndrome; single nucleotide polymorphism; testosterone

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TESTOSTERONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TESTOSTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; ALLELES; BODY MASS INDEX; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; TESTOSTERONE;

EID: 34047245082     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.10.006     Document Type: Article

References (44)

1. Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., and Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004) 2745-2749
2. Legro R.S., Driscoll D., Strauss III J.F., Fox J., and Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 95 (1998) 14956-14960
3. Kahsar-Miller M.D., Nixon C., Boots L.R., Go R.C., and Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 75 (2001) 53-58
4. DeUgarte C.M., Bartolucci A.A., and Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 83 (2005) 1454-1460
5. Takano H., and Komuro I. Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease. J Diabetes Complications 16 (2002) 108-114
6. Altshuler D., Hirschhorn J.N., Klannemark M., Lindgren C.M., Vohl M.C., Nemesh J., et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26 (2000) 76-80
7. Orio Jr. F., Palomba S., Cascella T., Di Biase S., Labella D., Russo T., et al. Lack of an association between peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 5110-5115
8. Hara M., Alcoser S.Y., Qaadir A., Beiswenger K.K., Cox N.J., and Ehrmann D.A. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab 87 (2002) 772-775
9. Hahn S., Fingerhut A., Khomtsiv U., Khomtsiv L., Tan S., Quadbeck B., et al. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 62 (2005) 573-579
10. Tok E.C., Aktas A., Ertunc D., Erdal E.M., and Dilek S. Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-gamma2 Pro12Ala genotype. Hum Reprod 20 (2005) 1590-1595
11. Orio Jr. F., Matarese G., Di Biase S., Palomba S., Labella D., Sanna V., et al. Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 5887-5892
12. San Millan J.L., Corton M., Villuendas G., Sancho J., Peral B., and Escobar-Morreale H.F. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 89 (2004) 2640-2646
13. Korhonen S., Heinonen S., Hiltunen M., Helisalmi S., Hippelainen M., Koivunen R., et al. Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Hum Reprod 18 (2003) 540-543
14. Haap M., Machicao F., Stefan N., Thamer C., Tschritter O., Schnuck F., et al. Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 113 (2005) 275-281
15. Wang Y., Wu X., Cao Y., Yi L., Fan H., and Chen J. Polymorphisms of the peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha genes in Chinese women with polycystic ovary syndrome. Fertil Steril 85 (2006) 1536-1540
16. Yilmaz M., Ergun M.A., Karakoc A., Yurtcu E., Cakir N., and Arslan M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol 22 (2006) 336-342
17. Zawadzki J.K., and Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A., Givens J.R., Haseltine F., and Merriam G.R. (Eds). Polycystic ovary syndrome (1992), Blackwell Scientific Publications, Cambridge 377-384
18. Hatch R., Rosenfield R.L., Kim M.H., and Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 140 (1981) 815-830
19. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., and Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
20. Levy J.C., Matthews D.R., and Hermans M.P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21 (1998) 2191-2192
21. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
22. Goodarzi M.O., Guo X., Taylor K.D., Quiñones M.J., Samayoa C., Yang H., et al. Determination and use of haplotypes: ethnic comparison and association of the lipoprotein lipase gene and coronary artery disease in Mexican-Americans. Genet Med 5 (2003) 322-327
23. Livak K.J. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14 (1999) 143-149
24. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
25. Qin Z.S., Niu T., and Liu J.S. Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 71 (2002) 1242-1247
26. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 57 (1995) 289-300
27. Azziz R., Ehrmann D., Legro R.S., Whitcomb R.W., Hanley R., Fereshetian A.G., et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86 (2001) 1626-1632
28. Dereli D., Dereli T., Bayraktar F., Ozgen A.G., and Yilmaz C. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J 52 (2005) 299-308
29. Hasegawa I., Murakawa H., Suzuki M., Yamamoto Y., Kurabayashi T., and Tanaka K. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 71 (1999) 323-327
30. Ehrmann D.A., Schneider D.J., Sobel B.E., Cavaghan M.K., Imperial J., Rosenfield R.L., et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82 (1997) 2108-2116
31. Sepilian V., and Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 90 (2005) 60-65
32. Vierhapper H., Nowotny P., and Waldhausl W. Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone. Metabolism 52 (2003) 230-232
33. Komar C.M., and Curry T.E. Inverse relationship between the expression of messenger ribonucleic acid for peroxisome proliferator-activated receptor gamma and P450 side chain cleavage in the rat ovary. Biol Reprod 69 (2003) 549-555
34. Mitwally M.F., Witchel S.F., and Casper R.F. Troglitazone: a possible modulator of ovarian steroidogenesis. J Soc Gynecol Invest 9 (2002) 163-167
35. Schoppee P.D., Garmey J.C., and Veldhuis J.D. Putative activation of the peroxisome proliferator-activated receptor gamma impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. Biol Reprod 66 (2002) 190-198
36. Seto-Young D., Paliou M., Schlosser J., Avtanski D., Park A., Patel P., et al. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 90 (2005) 6099-6105
37. Gasic S., Bodenburg Y., Nagamani M., Green A., and Urban R.J. Troglitazone inhibits progesterone production in porcine granulosa cells. Endocrinology 139 (1998) 4962-4966
38. Gasic S., Nagamani M., Green A., and Urban R.J. Troglitazone is a competitive inhibitor of 3beta-hydroxysteroid dehydrogenase enzyme in the ovary. Am J Obstet Gynecol 184 (2001) 575-579
39. Arlt W., Auchus R.J., and Miller W.L. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta-hydroxysteroid dehydrogenase. J Biol Chem 276 (2001) 16767-16771
40. Meirhaeghe A., Fajas L., Helbecque N., Cottel D., Lebel P., Dallongeville J., et al. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 7 (1998) 435-440
41. Yan Z.C., Zhu Z.M., Shen C.Y., Zhao Z.G., Ni Y.X., Zhong J., et al. Peroxisome proliferator-activated receptor gamma C-161T polymorphism and carotid artery atherosclerosis in metabolic syndrome. Zhonghua Yi Xue Za Zhi 84 (2004) 543-547
42. Wang X.L., Oosterhof J., and Duarte N. Peroxisome proliferator-activated receptor gamma C161→T polymorphism and coronary artery disease. Cardiovasc Res 44 (1999) 588-594
43. Legro R.S., Bentley-Lewis R., Driscoll D., Wang S.C., and Dunaif A. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab 87 (2002) 2128-2133
44. Norman R.J., Masters S., and Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril 66 (1996) 942-947